We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

146 hedge funds and large institutions have $1.73B invested in Akero Therapeutics in 2022 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 53 increasing their positions, 27 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

427% more capital invested

Capital invested by funds: $329M → $1.73B (+$1.41B)

206% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 16

133% more funds holding in top 10

Funds holding in top 10: 3 → 7 (+4)

96% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 27

29% more funds holding

Funds holding: 113 → 146 (+33)

5% more ownership

Funds ownership: 104.87% → 109.88% (+5%)

44% less call options, than puts

Call options by funds: $23.7M | Put options by funds: $42.1M

Holders
146
Holders Change
+33
Holders Change %
+29.2%
% of All Funds
2.52%
Holding in Top 10
7
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+133.33%
% of All Funds
0.12%
New
49
Increased
53
Reduced
27
Closed
16
Calls
$23.7M
Puts
$42.1M
Net Calls
-$18.4M
Net Calls Change
-$18.4M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$83.9M
2
APM
Avidity Partners Management
Texas
+$47.8M
3
BBA
Baker Bros. Advisors
New York
+$34.4M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$15.4M
5
RCM
RA Capital Management
Massachusetts
+$14.7M

Top Sellers

Rank Fund Capital Flow
1
VP
venBio Partners
California
-$24.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$21.7M
3
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$18.9M
4
HA
HHLR Advisors
Cayman Islands
-$10.4M
5
Millennium Management
Millennium Management
New York
-$4.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
26
Perceptive Advisors
New York
$14.6M +$6.58M +430,000 New
LGM
27
Logos Global Management
California
$13.6M +$6.12M +400,000 New
SCM
28
Silverarc Capital Management
Massachusetts
$10.2M +$607K +39,675 +15%
LFCM
29
Long Focus Capital Management
Puerto Rico
$9.94M +$30.6K +2,000 +0.7%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$9.92M -$1.08M -70,597 -20%
Northern Trust
31
Northern Trust
Illinois
$9.01M +$310K +20,232 +8%
Invesco
32
Invesco
Georgia
$8.1M +$3.64M +237,886 New
JP Morgan Chase
33
JP Morgan Chase
New York
$8.02M +$10.7K +702 +0.3%
IHAM
34
Integral Health Asset Management
New York
$7.83M -$888K -58,058 -20%
Charles Schwab
35
Charles Schwab
California
$7.25M +$737K +48,196 +29%
TLP
36
Tri Locum Partners
New York
$7.13M +$3.2M +209,248 New
Walleye Capital
37
Walleye Capital
New York
$6.95M +$3.12M +204,043 New
Morgan Stanley
38
Morgan Stanley
New York
$6.58M +$827K +54,050 +39%
Citadel Advisors
39
Citadel Advisors
Florida
$6.03M +$1.2M +78,551 +80%
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$5.79M +$1.51M +98,543 +138%
ACM
41
Altium Capital Management
New York
$4.77M +$2.14M +140,000 New
Two Sigma Investments
42
Two Sigma Investments
New York
$4.55M +$1.02M +66,911 +100%
CSS
43
Cubist Systematic Strategies
Connecticut
$3.99M +$1.48M +96,932 +479%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$3.84M +$410K +26,813 +31%
Ameriprise
45
Ameriprise
Minnesota
$3.36M +$1.51M +98,733 New
EI
46
EAM Investors
California
$2.88M +$1.29M +84,607 New
Simplex Trading
47
Simplex Trading
Illinois
$2.67M +$1.2M +78,268 +75,988%
OCA
48
Octagon Capital Advisors
New York
$2.55M +$1.15M +75,000 New
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$2.48M +$1.12M +72,977 New
Bank of America
50
Bank of America
North Carolina
$2.39M +$487K +31,842 +83%
1
2
3 4 5

AKRO Hedge Fund Activity: Q3 2022 in Review

146 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2022, worth a combined $1.73B — up 427% from $329M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new AKRO positions and 16 closed out — a net gain of 33 holders — while 53 added to existing stakes and 27 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $83.9M. The largest seller was venBio Partners, cutting an estimated $24.1M.

  • 146 institutional investors held Akero Therapeutics (AKRO) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $1.73B of Akero Therapeutics stock for Q3 2022, up 427% quarter-over-quarter.
  • 49 funds opened new Akero Therapeutics positions in Q3 2022 and 16 closed out, a net change of +33 holders.
  • The largest Akero Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $83.9M added.
  • The largest Akero Therapeutics seller in Q3 2022 was venBio Partners, an estimated $24.1M sold.

Based on aggregated 13F filings for Q3 2022.